Protective Effect of Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II)
Key facts
- Who runs it
- Nanjing Medical University
- Where
- China15 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 600 people enrolled
- Started
- 1 Jul 2022
- Ended
- 31 Jul 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-
- Blank control
- Record updated
- 14 September 2026
Who can take part
- Age
- 18 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset
- Patients with acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled
- The patients' age between 18 ~90 years old
- Agree to participate in the study and sign the informed consent
Who cannot take part
- Patients allergic to Thymosin α1
- Patients with mental diseases, drug and alcohol dependence
- Lactating women and pregnant women
- Refuse to participate in this study and refuse to sign the informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with acute aortic syndrome (AAS). Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with thymosin alpha 1 may be beneficial. This study was designed to test the hypothesis that the administration of thymosin alpha 1 during the acute phase of AAS will result in a reduced incidence of SIRS and MODS.
The 2 groups in the trial
- Thymosin alpha 1Treatment being tested
1.6 mg q12h for 5 days
Treatment: Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-
- Blank controlOther group
Standard care control; no placebo or sham thymosin alpha 1 injections were administered.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 14 September 2026